{
  "id": 20535652,
  "title": "Brain implant technology startup Science Corp. raises $400M to bring its medical devices to market",
  "url": "https://urgent.news/2026/11/18/brain-implant-technology-startup-science-corp-raises-400m-to-bring",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T01:58:12.000Z",
  "source": {
    "name": "SiliconANGLE",
    "slug": "siliconangle",
    "url": "https://siliconangle.com/2026/11/17/brain-implant-technology-startup-science-corp-raises-400m-to-bring-its-medical-devices-to-market/"
  },
  "original_language": "en",
  "account": "Brain-computer interface startup Science Corp. has secured $400 million in a late-stage funding round, bringing its valuation to $3.5 billion. The Series D round was led by Khosla Ventures, with participation from notable investors such as the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. The funding will enable the company to bring its flagship product, PRIMA, to the U.S. healthcare market after already gaining traction in Europe.\n\nPRIMA is a specialized chip implanted in the eyes of patients suffering from age-related macular degeneration (AMD), one of the leading causes of vision loss in older adults. The chip is paired with glasses that help restore partial vision to AMD sufferers and has already been approved for use in several European countries, including Germany. Science plans to offer PRIMA to patients who can afford it at a special unit at Moorfields Private Eye Hospital in London, though the exact cost has not been disclosed. The device is currently being reviewed by the FDA for potential approval in the U.S., with initial availability expected early next year.\n\nScience Corp. is also developing the Biohybrid implant, a direct brain implant built from cultured neurons combined with silicon chips and integrated with the brain's circuits. The company has identified Parkinson's disease as its first target for this technology but has not disclosed any other planned treatments. So far, Biohybrid has only been tested on animals, with human clinical trials planned within the next 16 months.",
  "summary": "Brain-computer interface company Science Corp. today revealed it has raised $400 million in a late-stage round of funding that brings its valuation to $3.5 billion. The Series D round, announced in a blog post today, was led by high-profile venture capital firm Khosla Ventures. It was joined by the Ackman Oxman Institute, Tenet Healthcare, 885 […] The post Brain implant technology startup Science…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}